<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979079</url>
  </required_header>
  <id_info>
    <org_study_id>IB2010-PREDYC</org_study_id>
    <nct_id>NCT03979079</nct_id>
  </id_info>
  <brief_title>Modeling Clinical Failure in Prostate Cancer Patients Based on a Two-stage Statistical Model</brief_title>
  <acronym>PREDYC</acronym>
  <official_title>Modeling Clinical Failure in Prostate Cancer Patients Based on a Two-stage Statistical Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biomarker series can indicate disease progression and predict clinical endpoints. When a&#xD;
      treatment is prescribed depending on the biomarker, confounding by indication might be&#xD;
      introduced if the treatment modifies the marker profile and risk of failure.&#xD;
&#xD;
      The two-stage model fitted within a Bayesian Markov Chain Monte Carlo framework is&#xD;
      particularly flexible to account for such data. Prostate-specific antigens in prostate cancer&#xD;
      patients treated with external beam radiation therapy can be monitored. In the presence of&#xD;
      rising prostate-specific antigens after external beam radiation therapy, salvage hormone&#xD;
      therapy can be prescribed to reduce both the prostate-specific antigens concentration and the&#xD;
      risk of clinical failure, an illustration of confounding by indication. The prognostic value&#xD;
      of hormone therapy and prostate-specific antigens trajectory on the risk of failure based on&#xD;
      a two-stage model within a Bayesian framework to assess the role of the prostate-specific&#xD;
      antigens profile on clinical failure while accounting for a secondary treatment prescribed by&#xD;
      indication. the aim of this research is to model prostate specific antigens using a&#xD;
      hierarchical piecewise linear trajectory with a random changepoint. Residual&#xD;
      prostate-specific antigens variability can be expressed as a function of prostate-specific&#xD;
      antigens concentration. Covariates in the survival model can include : hormone therapy,&#xD;
      baseline characteristics, and individual predictions of the prostate-specific antigens nadir&#xD;
      and timing and prostate-specific antigens slopes before and after the nadir as provided by&#xD;
      the longitudinal process.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two-stage modeling approach allows estimation of the regression coefficients in a&#xD;
      time-dependent Cox model, while addressing the limitations with the knowledge of the true&#xD;
      marker trajectory. In the first stage, the longitudinal process is modeled using a repeated&#xD;
      measures component model, such as a random effects model. In the second stage, estimated&#xD;
      characteristics of the longitudinal marker trajectory, such as slopes, are included as&#xD;
      covariates in a survival model to assess their prognostic value.&#xD;
&#xD;
      Our aim was to highlight the flexibility of a two-stage model fitted within a Bayesian Markov&#xD;
      Chain Monte Carlo (MCMC) framework. We applied this model to assess the prognostic value of&#xD;
      the prostate-specific antigens (PSA) profile (level and timing of the nadir; pre- and&#xD;
      post-nadir slopes) as well as salvage hormonal treatment (HT) on the risk of clinical failure&#xD;
      following external beam radiation therapy (EBRT) in the presence of confounding by&#xD;
      indication. We first present the longitudinal hierarchical PSA model that we developed&#xD;
      earlier. This model was particularly flexible since it allowed us to account for the presence&#xD;
      of a random changepoint as well as the modeling of the residual variability as a function of&#xD;
      the PSA concentration. We next extend the longitudinal model to a two-stage model by using&#xD;
      estimated parameters of the longitudinal process as covariates in a Cox proportional hazards&#xD;
      model to assess prognostic factors of clinical failure including baseline characteristics,&#xD;
      PSA trajectory, and HT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Failure After Initiation of Radiotherapy</measure>
    <time_frame>within 10 years following initiation of radiotherapy</time_frame>
    <description>Clinical failure is defined as any of the following events following initiation of radiotherapy: distant metastases, nodal recurrence, or any palpable or biopsy-detected local recurrence three years after radiation; any local recurrence within three years of RT if the most previous PSA was&gt;2 ng/ml; and death from prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Initiation of Salvage Therapy After Radiotherapy</measure>
    <time_frame>within 10 years following initiation of radiotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">2384</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Dataset of 2384 men included in three cohorts: University of Michigan, Ann Arbor, MI, USA&#xD;
        (UM); Radiation Therapy Oncology Group (RTOG 9406); and William Beaumont Hospital, Detroit,&#xD;
        MI, USA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically localized prostate cancer&#xD;
&#xD;
          -  Clinical stage T1 to T4&#xD;
&#xD;
          -  Node and metastasis negative&#xD;
&#xD;
          -  Treated with external beam radiation therapy (RT).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with baseline or planned hormonotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carine Bellera, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INSERM</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bellera C, Proust-Lima C, Joseph L, Richaud P, Taylor J, Sandler H, Hanley J, Mathoulin-Pélissier S. A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication. Stat Methods Med Res. 2018 Apr;27(4):1271-1281. doi: 10.1177/0962280216660127. Epub 2016 Sep 1.</citation>
    <PMID>27587597</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <results_first_submitted>November 25, 2020</results_first_submitted>
  <results_first_submitted_qc>November 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients</title>
          <description>Eligible Prostate Cancer Patients Undergoing EBRT Treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2384"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2384"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eligible Patients</title>
          <description>Eligible Prostate Cancer Patients Undergoing EBRT Treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2384"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Failure After Initiation of Radiotherapy</title>
        <description>Clinical failure is defined as any of the following events following initiation of radiotherapy: distant metastases, nodal recurrence, or any palpable or biopsy-detected local recurrence three years after radiation; any local recurrence within three years of RT if the most previous PSA was&gt;2 ng/ml; and death from prostate cancer.</description>
        <time_frame>within 10 years following initiation of radiotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Failure After Initiation of Radiotherapy</title>
          <description>Clinical failure is defined as any of the following events following initiation of radiotherapy: distant metastases, nodal recurrence, or any palpable or biopsy-detected local recurrence three years after radiation; any local recurrence within three years of RT if the most previous PSA was&gt;2 ng/ml; and death from prostate cancer.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Initiation of Salvage Therapy After Radiotherapy</title>
        <time_frame>within 10 years following initiation of radiotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Eligible patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Initiation of Salvage Therapy After Radiotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Prognostic Value of Hormone Therapy on the Risk of Clinical Failure.</title>
        <time_frame>within 10 years following initiation of radiotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>Eligible patients</description>
          </group>
        </group_list>
        <measure>
          <title>Prognostic Value of Hormone Therapy on the Risk of Clinical Failure.</title>
          <units>hazard ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2384"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.14" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
            <other_analysis_desc>Two-stage model within a Bayesian framework to assess the role of the prostate-specific antigens profile on clinical failure while accounting for a secondary treatment prescribed by indication. Prostatespecific antigens modeled using a hierarchical piecewise linear trajectory with a random changepoint. Residual prostate-specific antigens variability was expressed as a function of prostate-specific antigens concentration. Covariates in the survival model included hormone therapy, baseline characteristics, and individual predictions of the prostate-specific antigens nadir and timing and prostate-specific antigens slopes before and after the nadir as provided by the longitudinal process.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 10 years following initiation of radiotherapy</time_frame>
      <desc>This study is a retrospective analysis focussing on the association between the longitudinal PSA trajectory and the time to clinical failure. As such, we did not report on safety.&#xD;
Serious and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>Eligible patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2384"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Carine Bellera</name_or_title>
      <organization>Institut Bergonié</organization>
      <phone>33 0 5 56 33 04 95</phone>
      <email>c.bellera@bordeaux.unicancer.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

